Literature DB >> 14760748

Key role of mast cells and their major secretory products in inflammatory bowel disease.

Shao-Heng He1.   

Abstract

Historically, mast cells were known as a key cell type involved in type I hypersensitivity. Until last two decades, this cell type was recognized to be widely involved in a number of non-allergic diseases including inflammatory bowel disease (IBD). Markedly increased numbers of mast cells were observed in the mucosa of the ileum and colon of patients with IBD, which was accompanied by great changes of the content in mast cells such as dramatically increased expression of TNFalpha, IL-16 and substance P. The evidence of mast cell degranulation was found in the wall of intestine from patients with IBD with immunohistochemistry technique. The highly elevated histamine and tryptase levels were detected in mucosa of patients with IBD, strongly suggesting that mast cell degranulation is involved in the pathogenesis of IBD. However, little is known of the actions of histamine, tryptase, chymase and carboxypeptidase in IBD. Over the last decade, heparin has been used to treat IBD in clinical practice. The low molecular weight heparin (LMWH) was effective as adjuvant therapy, and the patients showed good clinical and laboratory response with no serious adverse effects. The roles of PGD2, LTC4, PAF and mast cell cytokines in IBD were also discussed. Recently, a series of experiments with dispersed colon mast cells suggested there should be at least two pathways in man for mast cells to amplify their own activation-degranulation signals in an autocrine or paracrine manner. The hypothesis is that mast cell secretogogues induce mast cell degranulation, release histamine, then stimulate the adjacent mast cells or positively feedback to further stimulate its host mast cells through H1 receptor. Whereas released tryptase acts similarly to histamine, but activates mast cells through its receptor PAR-2. The connections between current anti-IBD therapies or potential therapies for IBD with mast cells were discussed, implicating further that mast cell is a key cell type that is involved in the pathogenesis of IBD. In conclusion, while pathogenesis of IBD remains unclear, the key role of mast cells in this group of diseases demonstrated in the current review implicates strongly that IBD is a mast cell associated disease. Therefore, close attentions should be paid to the role of mast cells in IBD.

Entities:  

Mesh:

Year:  2004        PMID: 14760748      PMCID: PMC4724914          DOI: 10.3748/wjg.v10.i3.309

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  183 in total

1.  Induction of tryptase and histamine release from human colon mast cells by IgE dependent or independent mechanisms.

Authors:  Shao-Heng He; Hua Xie; Yong-Song He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

2.  Dual effect of chronic nicotine administration: augmentation of jejunitis and amelioration of colitis induced by iodoacetamide in rats.

Authors:  R Eliakim; F Karmeli; P Cohen; S N Heyman; D Rachmilewitz
Journal:  Int J Colorectal Dis       Date:  2001-02       Impact factor: 2.571

3.  Mast cells in the synovium and synovial fluid in osteoarthritis.

Authors:  G Dean; J A Hoyland; J Denton; R P Donn; A J Freemont
Journal:  Br J Rheumatol       Date:  1993-08

4.  Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis.

Authors:  A Nakamura; K Yamazaki; K Suzuki; S Sato
Journal:  Am J Gastroenterol       Date:  1997-12       Impact factor: 10.864

Review 5.  Medical therapy of inflammatory bowel disease for the 21st century.

Authors:  M Robinson
Journal:  Eur J Surg Suppl       Date:  1998

6.  Mast cell activation by Mycobacterium tuberculosis: mediator release and role of CD48.

Authors:  Samira Muñoz; Rogelio Hernández-Pando; Soman N Abraham; Jose Antonio Enciso
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

7.  Heterogeneity of human mast cells.

Authors:  E S Schulman; A Kagey-Sobotka; D W MacGlashan; N F Adkinson; S P Peters; R P Schleimer; L M Lichtenstein
Journal:  J Immunol       Date:  1983-10       Impact factor: 5.422

8.  A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase.

Authors:  S He; M D Gaça; A F Walls
Journal:  J Pharmacol Exp Ther       Date:  1998-07       Impact factor: 4.030

9.  Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

Authors:  R C Evans; V S Wong; A I Morris; J M Rhodes
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171

10.  Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery.

Authors:  P Laine; M Kaartinen; A Penttilä; P Panula; T Paavonen; P T Kovanen
Journal:  Circulation       Date:  1999-01-26       Impact factor: 29.690

View more
  77 in total

Review 1.  Histamine H₄ receptors in the gastrointestinal tract.

Authors:  A Deiteren; J G De Man; P A Pelckmans; B Y De Winter
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

Review 2.  Mechanisms for amplified mediator release from colonic mast cells: implications for intestinal inflammatory diseases.

Authors:  Kim E Barrett
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

Review 3.  [Systemic mastocytosis--definition of an internal disease].

Authors:  Jürgen Homann; Ulrich W Kolck; Andreas Ehnes; Thomas Frieling; Martin Raithel; Gerhard J Molderings
Journal:  Med Klin (Munich)       Date:  2010-09-08

Review 4.  Chymase inhibition as a pharmacological target: a role in inflammatory and functional gastrointestinal disorders?

Authors:  S Heuston; N P Hyland
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

5.  The role of eosinophils in inflammatory bowel disease.

Authors:  S Al-Haddad; R H Riddell
Journal:  Gut       Date:  2005-12       Impact factor: 23.059

6.  [Anaphylactoid reaction in occult systemic mastocytosis. A rare dermatologic emergency ].

Authors:  H Ständer; K Beier; D Metze; R Brehler
Journal:  Hautarzt       Date:  2005-03       Impact factor: 0.751

7.  Mast cells are an essential component of human radiation proctitis and contribute to experimental colorectal damage in mice.

Authors:  Karl Blirando; Fabien Milliat; Isabelle Martelly; Jean-Christophe Sabourin; Marc Benderitter; Agnès François
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 8.  Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation.

Authors:  Ashkan Farhadi; Jeremy-Z Fields; Ali Keshavarzian
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

Review 9.  Whipple's disease: a macrophage disease.

Authors:  Benoît Desnues; Melanie Ihrig; Didier Raoult; Jean-Louis Mege
Journal:  Clin Vaccine Immunol       Date:  2006-02

Review 10.  Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia.

Authors:  Craig A Friesen; Jennifer V Schurman; Jennifer M Colombo; Susan M Abdel-Rahman
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.